Symptomatic Severe Bradycardia during Pazopanib Treatment Pazopanib Tedavisi Sırasında Semptomatik Şiddetli Bradikardi
Turk Kardiyoloji Dernegi Arsivi, cilt.53, sa.2, ss.140-142, 2025 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 53 Sayı: 2
- Basım Tarihi: 2025
- Doi Numarası: 10.5543/tkda.2024.03788
- Dergi Adı: Turk Kardiyoloji Dernegi Arsivi
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), Directory of Open Access Journals, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.140-142
- Anahtar Kelimeler: Angiosarcoma, cardiotoxicity, pazopanib, permissive cardiotoxicity
- İstanbul Üniversitesi Adresli: Evet
Özet
Pazopanib, a tyrosine kinase inhibitor that targets growth factor receptors, is associated with various side effects, including bradycardia. We report a severe case of symptomatic bradycardia, with a heart rate dropping to 28 beats per minute, in a patient with cardiac angiosarcoma treated with 800 mg/day of pazopanib. Reducing the dosage to 600 mg/day improved the heart rate to 53 beats per minute. This case highlights the risk of severe bradycardia associated with pazopanib, emphasizing the need for vigilant heart rate monitoring.